

REMARKS

Applicant has cancelled the claims 1-27 from parent application 09/912,710 and claims 28-51 from first divisional application 10/268,350 and replaced claim 51 with claim 52 in independent form to reflect the definitions of the various groups in the compound 1. This removes the claims directed to the compounds, composition and use as reflected in the election of Group I drawn to claims 28-50 of the first divisional application, and the cancelled claims 1-27 of the parent. The new claim 52 replaces claim 51 to intermediate compounds of formula 1, and refers to non-elected Group II pursuant to the restriction requirement for the first divisional application.

The Abstract has also been modified to more completely describe the general nature of the invention.

The Cross-Reference to Related Application has been changed to indicate this application is a divisional application of first divisional Application Number 10/268,350 filed October 10, 2002.

The same amendments made in the parent and first divisional applications have again been made herein to clarify minor informalities. Applicant has corrected inadvertent typographical errors appearing on page 111, line 19, and page 112, lines 3, 12, 13 and 19. The compounds were inadvertently referred to as "-7-azaindole" compounds, whereas in fact they are "-6-azaindole" compounds. These are specifically compounds 36 and 37 which are prepared according to Scheme 12 on page 49, where the correct structural formulas are shown indicating these compounds to be -6-azaindoles.


Early and favorable action is earnestly requested.

CONCLUSION

If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited. If there are any additional fees due in connection with the filing of this amendment, please charge the fees to the undersigned's Deposit Account No. 19-3880. If any extensions or fees are not accounted for, such extension is requested and the associated fee should be charged to our deposit account.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7787



Samuel J. DuBoff
Attorney for Applicants
Reg. No. 25,969

Date: 7/16/03